MINNETONKA, Minn., Feb. 10 MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant. This individual was enrolled Friday, February 5th by Dr. Haluk Tezcan at the Kootenia Cancer Center in Post Falls, ID.
Advertisement
The registry, named COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), was built using ENLIGHTEN®, MedNet's industry-leading EDC/eClinical technology solution. This represents the 5th disease-specific registry built and deployed by MedNet Solutions within the last two years.
Advertisement
"We saw the importance of developing a global PTCL-specific registry that addresses the urgent need to better understand the real-world disease management across multiple treatment regimens, such as drug therapy, stem cell transplant and radiation therapy," stated Dvorit Samid, Ph.D., vice president, Medical Affairs at Allos Therapeutics. "MedNet has done an excellent job of initiating the registry and meeting critical timelines. They worked closely with a group of prominent international multi-disciplinary experts, serving as a steering committee, to develop this new PTCL registry - named COMPLETE - to prospectively study treatment patterns and patient outcomes. We are committed to this important initiative and believe that the data obtained will eventually help practitioners optimize treatment for patients with aggressive PTCL."
The COMPLETE registry is a global 5 year observational study that will enroll newly-diagnosed PTCL patients and collect data on longitudinal treatment patterns and outcomes. The approximately 75 sites expected to participate will represent academic, hospital and community practices across the U.S. and Europe.
"MedNet Solutions is excited to work with Allos to build a registry that will help the healthcare community increase their understanding of this terrible disease," commented John M. (Rob) Robertson, president and CEO of MedNet Solutions. "ENLIGHTEN will provide Allos with the proven and efficient infrastructure needed to collect and analyze treatment data and outcomes.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of a folate analogue metabolic inhibitor for hematologic malignancies and solid tumor indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com.
About MedNet Solutions
MedNet Solutions is a leading healthcare technology company specializing in clinical study management systems designed for the global life sciences market. Applying critical insight, proven technology and unwavering support, MedNet delivers powerful, flexible and easy-to-use web-based solutions that support our customers' clinical studies, registries and investigator initiated trials. Since 2000, MedNet has successfully supported leading pharmaceutical, medical device, and biotechnology organizations on projects spanning 6 continents and more than 40 countries. MedNet delivers a superior customer experience from beginning to end. For more information, please visit www.mednetstudy.com.
Contact Information: Dirk H. Nelson Marketing Manager 601 Carlson Parkway, Suite 605 Minnetonka, MN 55305 USA (763) 258-2735
SOURCE MedNet Solutions
